XML 43 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
Revenue Recognition and Significant Collaborative Research and Development Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2010
Mar. 31, 2016
Mar. 31, 2015
Jun. 30, 2017
Dec. 31, 2015
Mitsubishi Tanabe          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Up-front license fees         $ 30,000,000
Collaborative agreement maximum additional payment to receive         85,000,000
Patent rights period       The longer of ten years or the life of the related patent rights.  
Clinical trial cost         $ 12,000,000
Collaborative arrangement right description       Under the terms of the Company’s agreement with Mitsubishi Tanabe, the collaboration effort between the parties to advance valbenazine towards commercialization in Japan and other select Asian markets is governed by a joint steering committee and joint development committee with representatives from both the Company and Mitsubishi Tanabe. There are no performance, cancellation, termination or refund provisions in the agreement that would have a material financial consequence to the Company. The Company does not directly control when event-based payments will be achieved or when royalty payments will begin. Mitsubishi Tanabe may terminate the agreement at its discretion upon 180 days’ written notice to the Company. In such event, all valbenazine product rights for Japan and other select Asian markets would revert to the Company.  
Collaboration termination notice period       180 days  
Revenues recognized under collaboration agreement     $ 19,800,000    
Deferred revenues under collaboration     $ 10,200,000    
AbbVie          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Patent rights period       Ten years or the life of the related patent rights.  
Collaborative arrangement right description       The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.  
Collaboration termination notice period       180 days  
Revenues recognized under collaboration agreement   $ 15,000,000      
AbbVie          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Up-front license fees $ 75,000,000        
Amount remains outstanding under collaboration agreement       $ 485,000,000  
AbbVie | Development and Regulatory Milestone Payments          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Collaborative agreement maximum additional payment to receive       480,000,000  
Collaborative agreement payment received       45,000,000  
AbbVie | Commercial Milestone Payments          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Collaborative agreement maximum additional payment to receive       $ 50,000,000